Dubai – United Arab Emirates, 15 August, 2018: Held under the patronage of His Excellency Sheikh Nahyan bin Mubarak Al Nahyan, Cabinet Minister and Minister of Tolerance, United Arab Emirates and President of UAE Genetic Disease Association, Dubai is set to host the 10th UAE Cancer Congress – UAECC, an event dedicated to oncology professionals in Dubai and focusing on a broad range of topics in Oncology Care and Management, from the 11th to the 13th of October 2018, at the InterContinental Dubai Festival City.

In its 10th edition, UAECC aims to foster best practices in cancer care and management, raise treatment standards at the clinicians’ level for better patient care, discuss latest advances in cancer care, research studies and new treatment methodologies for various cancer diseases.

During the 3-day event, UAECC is expected to attract over 2500 visitors and more than 40 participating sponsor companies, witness the participation of more than 200 speakers from over 75 countries, feature 17 hands-on workshops including a ‘Live Workshop from Tata Memorial hospital in India’ and showcase over 200 poster presentations designed by students and professionals from the UAE and abroad.

Commenting on the significance of the 10th UAE Cancer Congress in Dubai, Dr. Shaheenah Dawood, President, UAECC, Consultant Medical Oncologist, Mediclinic City Hospital, UAE said, “Our mission at UAE Cancer Congress is to play a crucial part in preparing the community for overcoming issues and challenges in preventing the onset of cancer. As part of our efforts in effectively overcoming this disease in the Middle East and Asia Pacific region, we strive to support the oncology community by partnering, learning and building collaborations with various organizations and coming up with unique initiatives to allow for progress in cancer research. Furthermore, UAECC is the only such congress in the middle east, which has been consistently bringing cutting edge medical research and technology to our doorsteps in the past 10 years.”

She added, “Cancer treatment is undergoing a revolution where the influx of novel therapies derived from basic research on our immune system has shifted the landscape of modern medicine. In addition, new discoveries in immunotherapy, which seek to use the body’s immune system to help fight cancer, are proving to have a profound impact on cancer treatment and prevention. As research and the development of new therapies for different types of cancers is a continuous process requiring great effort, we believe that UAECC is an ideal platform which will serve the needs of the medical and pharmaceutical industry in overcoming this disease.”

UAECC 2018 will be introducing the 1st Asia Pac Middle East Biosimilar Summit on the sidelines of its main conference, with the aim of building a viable roadmap on the advantages of using biosimilar pharma products as compared to generic drugs while also offering industry experts an opportunity to discuss the pros & cons and misconceptions about biosimilar pharmaceutical products, exchange latest data from the ‘Global Biosimilars Landscape’, explore Case Studies and support pharma and Biopharma companies to succeed in the Global Biosimilar Market.

Cancer Stats in the Gulf region:

While the world of medicine has made rapid strides and great progress in our understanding about cancer and its prevention, cancer still remains the most threatening challenge for medical fraternity, communities and peoples without exception. According to the Gulf Cancer Monitoring Center, it is predicted that 21,000 new cancer cases will occur among GCC nationals by 2030, while the number of cancer cases were 8065 in 1998 and 11,894 in 2009. More figures released by the Health Department of Abu Dhabi show that there are 4,500 new cases of cancer each year, with breast, colorectal and lung cancers, widely impacting patients in the region.

The 10th UAECC, being held until the 13th of October, is organized by INDEX Conferences and Exhibitions – a member of INDEX Holding in partnership with UAE Genetic Disease Association, Oncology Nursing Society, Emirates Urological Society, Tata Memorial Centre and Indian Cooperative Oncology Network, India.